Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73

1.

Safe eradication of large established tumors using neovasculature-targeted tumor necrosis factor-based therapies.

Huyghe L, Van Parys A, Cauwels A, Van Lint S, De Munter S, Bultinck J, Zabeau L, Hostens J, Goethals A, Vanderroost N, Verhee A, Uzé G, Kley N, Peelman F, Vandekerckhove B, Brouckaert P, Tavernier J.

EMBO Mol Med. 2020 Jan 8:e11223. doi: 10.15252/emmm.201911223. [Epub ahead of print]

2.

Targeting interferon activity to dendritic cells enables in vivo tolerization and protection against EAE in mice.

Cauwels A, Van Lint S, Catteeuw D, Pang S, Paul F, Rogge E, Verhee A, Prinz M, Kley N, Uzé G, Tavernier J.

J Autoimmun. 2019 Feb;97:70-76. doi: 10.1016/j.jaut.2018.10.010. Epub 2018 Nov 19.

PMID:
30467068
3.

Signal Propagation in Sensing and Reciprocating Cellular Systems with Spatial and Structural Heterogeneity.

Hodgkinson A, Uzé G, Radulescu O, Trucu D.

Bull Math Biol. 2018 Jul;80(7):1900-1936. doi: 10.1007/s11538-018-0439-x. Epub 2018 May 2.

PMID:
29721746
4.

A safe and highly efficient tumor-targeted type I interferon immunotherapy depends on the tumor microenvironment.

Cauwels A, Van Lint S, Garcin G, Bultinck J, Paul F, Gerlo S, Van der Heyden J, Bordat Y, Catteeuw D, De Cauwer L, Rogge E, Verhee A, Uzé G, Tavernier J.

Oncoimmunology. 2017 Nov 27;7(3):e1398876. doi: 10.1080/2162402X.2017.1398876. eCollection 2018.

5.

Delivering Type I Interferon to Dendritic Cells Empowers Tumor Eradication and Immune Combination Treatments.

Cauwels A, Van Lint S, Paul F, Garcin G, De Koker S, Van Parys A, Wueest T, Gerlo S, Van der Heyden J, Bordat Y, Catteeuw D, Rogge E, Verhee A, Vandekerckhove B, Kley N, Uzé G, Tavernier J.

Cancer Res. 2018 Jan 15;78(2):463-474. doi: 10.1158/0008-5472.CAN-17-1980. Epub 2017 Nov 29.

6.

Assessment of mTOR-Dependent Translational Regulation of Interferon Stimulated Genes.

Livingstone M, Sikström K, Robert PA, Uzé G, Larsson O, Pellegrini S.

PLoS One. 2015 Jul 24;10(7):e0133482. doi: 10.1371/journal.pone.0133482. eCollection 2015.

7.

Receptor dimerization dynamics as a regulatory valve for plasticity of type I interferon signaling.

Wilmes S, Beutel O, Li Z, Francois-Newton V, Richter CP, Janning D, Kroll C, Hanhart P, Hötte K, You C, Uzé G, Pellegrini S, Piehler J.

J Cell Biol. 2015 May 25;209(4):579-93. doi: 10.1083/jcb.201412049.

8.

IFNA2: The prototypic human alpha interferon.

Paul F, Pellegrini S, Uzé G.

Gene. 2015 Aug 10;567(2):132-7. doi: 10.1016/j.gene.2015.04.087. Epub 2015 May 14. Review.

9.

High efficiency targeting of IFN-α activity: possible applications in fighting tumours and infections.

Uzé G, Tavernier J.

Cytokine Growth Factor Rev. 2015 Apr;26(2):179-82. doi: 10.1016/j.cytogfr.2014.10.006. Epub 2014 Oct 31. Review.

PMID:
25466630
10.

Harnessing Mechanistic Knowledge on Beneficial Versus Deleterious IFN-I Effects to Design Innovative Immunotherapies Targeting Cytokine Activity to Specific Cell Types.

Tomasello E, Pollet E, Vu Manh TP, Uzé G, Dalod M.

Front Immunol. 2014 Oct 30;5:526. doi: 10.3389/fimmu.2014.00526. eCollection 2014. Review.

11.

Baseline sensitivity of T cells to alpha-IFN correlates with sustained virological response to IFN-based triple therapy in HCV infection.

Sultanik PS, Casrouge A, Alanio C, Mottez E, Rosa-Hézode I, Hézode C, Renard P, Bousquet L, Pellet P, Uzé G, Pol S, Albert ML, Mallet V.

J Viral Hepat. 2015 Jun;22(6):524-34. doi: 10.1111/jvh.12355. Epub 2014 Nov 10.

PMID:
25382001
12.

Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy.

Sistigu A, Yamazaki T, Vacchelli E, Chaba K, Enot DP, Adam J, Vitale I, Goubar A, Baracco EE, Remédios C, Fend L, Hannani D, Aymeric L, Ma Y, Niso-Santano M, Kepp O, Schultze JL, Tüting T, Belardelli F, Bracci L, La Sorsa V, Ziccheddu G, Sestili P, Urbani F, Delorenzi M, Lacroix-Triki M, Quidville V, Conforti R, Spano JP, Pusztai L, Poirier-Colame V, Delaloge S, Penault-Llorca F, Ladoire S, Arnould L, Cyrta J, Dessoliers MC, Eggermont A, Bianchi ME, Pittet M, Engblom C, Pfirschke C, Préville X, Uzè G, Schreiber RD, Chow MT, Smyth MJ, Proietti E, André F, Kroemer G, Zitvogel L.

Nat Med. 2014 Nov;20(11):1301-9. doi: 10.1038/nm.3708. Epub 2014 Oct 26.

PMID:
25344738
13.

Human intracellular ISG15 prevents interferon-α/β over-amplification and auto-inflammation.

Zhang X, Bogunovic D, Payelle-Brogard B, Francois-Newton V, Speer SD, Yuan C, Volpi S, Li Z, Sanal O, Mansouri D, Tezcan I, Rice GI, Chen C, Mansouri N, Mahdaviani SA, Itan Y, Boisson B, Okada S, Zeng L, Wang X, Jiang H, Liu W, Han T, Liu D, Ma T, Wang B, Liu M, Liu JY, Wang QK, Yalnizoglu D, Radoshevich L, Uzé G, Gros P, Rozenberg F, Zhang SY, Jouanguy E, Bustamante J, García-Sastre A, Abel L, Lebon P, Notarangelo LD, Crow YJ, Boisson-Dupuis S, Casanova JL, Pellegrini S.

Nature. 2015 Jan 1;517(7532):89-93. doi: 10.1038/nature13801. Epub 2014 Oct 12.

14.

High efficiency cell-specific targeting of cytokine activity.

Garcin G, Paul F, Staufenbiel M, Bordat Y, Van der Heyden J, Wilmes S, Cartron G, Apparailly F, De Koker S, Piehler J, Tavernier J, Uzé G.

Nat Commun. 2014;5:3016. doi: 10.1038/ncomms4016.

PMID:
24398568
15.

IFNα signaling through PKC-θ is essential for antitumor NK cell function.

Comet NR, Aguiló JI, Rathoré MG, Catalán E, Garaude J, Uzé G, Naval J, Pardo J, Villalba M, Anel A.

Oncoimmunology. 2014 Nov 14;3(8):e948705. eCollection 2014.

16.

Differential activity of type I interferon subtypes for dendritic cell differentiation.

Garcin G, Bordat Y, Chuchana P, Monneron D, Law HK, Piehler J, Uzé G.

PLoS One. 2013;8(3):e58465. doi: 10.1371/journal.pone.0058465. Epub 2013 Mar 5.

17.

USP18 establishes the transcriptional and anti-proliferative interferon α/β differential.

Francois-Newton V, Livingstone M, Payelle-Brogard B, Uzé G, Pellegrini S.

Biochem J. 2012 Sep 15;446(3):509-16. doi: 10.1042/BJ20120541.

PMID:
22731491
18.

USP18-based negative feedback control is induced by type I and type III interferons and specifically inactivates interferon α response.

François-Newton V, Magno de Freitas Almeida G, Payelle-Brogard B, Monneron D, Pichard-Garcia L, Piehler J, Pellegrini S, Uzé G.

PLoS One. 2011;6(7):e22200. doi: 10.1371/journal.pone.0022200. Epub 2011 Jul 14.

19.

Self-controlled monofunctionalization of quantum dots for multiplexed protein tracking in live cells.

You C, Wilmes S, Beutel O, Löchte S, Podoplelowa Y, Roder F, Richter C, Seine T, Schaible D, Uzé G, Clarke S, Pinaud F, Dahan M, Piehler J.

Angew Chem Int Ed Engl. 2010 Jun 1;49(24):4108-12. doi: 10.1002/anie.200907032. No abstract available.

PMID:
20432494
20.

Receptor density is key to the alpha2/beta interferon differential activities.

Moraga I, Harari D, Schreiber G, Uzé G, Pellegrini S.

Mol Cell Biol. 2009 Sep;29(17):4778-87. doi: 10.1128/MCB.01808-08. Epub 2009 Jun 29.

21.

Interferons at age 50: past, current and future impact on biomedicine.

Borden EC, Sen GC, Uze G, Silverman RH, Ransohoff RM, Foster GR, Stark GR.

Nat Rev Drug Discov. 2007 Dec;6(12):975-90. Review.

22.

The receptor of the type I interferon family.

Uzé G, Schreiber G, Piehler J, Pellegrini S.

Curr Top Microbiol Immunol. 2007;316:71-95. Review.

PMID:
17969444
23.

Comparable potency of IFNalpha2 and IFNbeta on immediate JAK/STAT activation but differential down-regulation of IFNAR2.

Marijanovic Z, Ragimbeau J, van der Heyden J, Uzé G, Pellegrini S.

Biochem J. 2007 Oct 1;407(1):141-51.

24.

IL-28 and IL-29: newcomers to the interferon family.

Uzé G, Monneron D.

Biochimie. 2007 Jun-Jul;89(6-7):729-34. Epub 2007 Jan 27. Review.

PMID:
17367910
25.

Differential receptor subunit affinities of type I interferons govern differential signal activation.

Jaks E, Gavutis M, Uzé G, Martal J, Piehler J.

J Mol Biol. 2007 Feb 16;366(2):525-39. Epub 2006 Nov 18.

PMID:
17174979
26.

Performing quantitative reverse-transcribed polymerase chain reaction experiments.

Lutfalla G, Uze G.

Methods Enzymol. 2006;410:386-400. Review.

PMID:
16938562
27.

Negative regulation of type I interferon signaling: facts and mechanisms.

Coccia EM, Uzé G, Pellegrini S.

Cell Mol Biol (Noisy-le-grand). 2006 May 15;52(1):77-87. Review.

PMID:
16914099
28.

Differential responsiveness to IFN-alpha and IFN-beta of human mature DC through modulation of IFNAR expression.

Severa M, Remoli ME, Giacomini E, Ragimbeau J, Lande R, Uzé G, Pellegrini S, Coccia EM.

J Leukoc Biol. 2006 Jun;79(6):1286-94. Epub 2006 Apr 19.

PMID:
16624932
29.

Tumor necrosis factor alpha enhances influenza A virus-induced expression of antiviral cytokines by activating RIG-I gene expression.

Matikainen S, Sirén J, Tissari J, Veckman V, Pirhonen J, Severa M, Sun Q, Lin R, Meri S, Uzé G, Hiscott J, Julkunen I.

J Virol. 2006 Apr;80(7):3515-22.

30.

Inquiring into the differential action of interferons (IFNs): an IFN-alpha2 mutant with enhanced affinity to IFNAR1 is functionally similar to IFN-beta.

Jaitin DA, Roisman LC, Jaks E, Gavutis M, Piehler J, Van der Heyden J, Uze G, Schreiber G.

Mol Cell Biol. 2006 Mar;26(5):1888-97.

31.

Interferon-lambda-treated dendritic cells specifically induce proliferation of FOXP3-expressing suppressor T cells.

Mennechet FJ, Uzé G.

Blood. 2006 Jun 1;107(11):4417-23. Epub 2006 Feb 14.

PMID:
16478884
32.

Transcriptional profiles discriminate bone marrow-derived and synovium-derived mesenchymal stem cells.

Djouad F, Bony C, Häupl T, Uzé G, Lahlou N, Louis-Plence P, Apparailly F, Canovas F, Rème T, Sany J, Jorgensen C, Noël D.

Arthritis Res Ther. 2005;7(6):R1304-15. Epub 2005 Sep 20.

33.

Interferon-alpha and -beta differentially regulate osteoclastogenesis: role of differential induction of chemokine CXCL11 expression.

Coelho LF, Magno de Freitas Almeida G, Mennechet FJ, Blangy A, Uzé G.

Proc Natl Acad Sci U S A. 2005 Aug 16;102(33):11917-22. Epub 2005 Aug 4.

34.

Functional cartography of the ectodomain of the type I interferon receptor subunit ifnar1.

Lamken P, Gavutis M, Peters I, Van der Heyden J, Uzé G, Piehler J.

J Mol Biol. 2005 Jul 15;350(3):476-88.

PMID:
15946680
35.

Viral infection and Toll-like receptor agonists induce a differential expression of type I and lambda interferons in human plasmacytoid and monocyte-derived dendritic cells.

Coccia EM, Severa M, Giacomini E, Monneron D, Remoli ME, Julkunen I, Cella M, Lande R, Uzé G.

Eur J Immunol. 2004 Mar;34(3):796-805. doi: 10.1002/eji.200324610.

36.

The GTP/GDP cycling of rho GTPase TCL is an essential regulator of the early endocytic pathway.

de Toledo M, Senic-Matuglia F, Salamero J, Uze G, Comunale F, Fort P, Blangy A.

Mol Biol Cell. 2003 Dec;14(12):4846-56. Epub 2003 Sep 5. Erratum in: Mol Biol Cell. 2004 Apr;15(4):preceding table of contents.

37.

The tyrosine kinase Tyk2 controls IFNAR1 cell surface expression.

Ragimbeau J, Dondi E, Alcover A, Eid P, Uzé G, Pellegrini S.

EMBO J. 2003 Feb 3;22(3):537-47.

38.

Down-modulation of responses to type I IFN upon T cell activation.

Dondi E, Rogge L, Lutfalla G, Uzé G, Pellegrini S.

J Immunol. 2003 Jan 15;170(2):749-56.

39.

Selective expression of type I IFN genes in human dendritic cells infected with Mycobacterium tuberculosis.

Remoli ME, Giacomini E, Lutfalla G, Dondi E, Orefici G, Battistini A, Uzé G, Pellegrini S, Coccia EM.

J Immunol. 2002 Jul 1;169(1):366-74.

40.

Down-modulation of type 1 interferon responses by receptor cross-competition for a shared Jak kinase.

Dondi E, Pattyn E, Lutfalla G, Van Ostade X, Uzé G, Pellegrini S, Tavernier J.

J Biol Chem. 2001 Dec 14;276(50):47004-12. Epub 2001 Oct 15.

41.

The receptor interaction region of Tyk2 contains a motif required for its nuclear localization.

Ragimbeau J, Dondi E, Vasserot A, Romero P, Uzé G, Pellegrini S.

J Biol Chem. 2001 Aug 17;276(33):30812-8. Epub 2001 Jun 8.

42.

A dual role for the kinase-like domain of the tyrosine kinase Tyk2 in interferon-alpha signaling.

Yeh TC, Dondi E, Uze G, Pellegrini S.

Proc Natl Acad Sci U S A. 2000 Aug 1;97(16):8991-6.

43.

The type I interferon receptor: structure, function, and evolution of a family business.

Mogensen KE, Lewerenz M, Reboul J, Lutfalla G, Uzé G.

J Interferon Cytokine Res. 1999 Oct;19(10):1069-98. Review.

PMID:
10547147
44.

Comparative genomic analysis of the interferon/interleukin-10 receptor gene cluster.

Reboul J, Gardiner K, Monneron D, Uzé G, Lutfalla G.

Genome Res. 1999 Mar;9(3):242-50.

45.

Type I interferons: expression and signalization.

Doly J, Civas A, Navarro S, Uze G.

Cell Mol Life Sci. 1998 Oct;54(10):1109-21. Review.

PMID:
9817990
46.

Shared receptor components but distinct complexes for alpha and beta interferons.

Lewerenz M, Mogensen KE, Uzé G.

J Mol Biol. 1998 Sep 25;282(3):585-99.

PMID:
9737924
47.

Specific contribution of Tyk2 JH regions to the binding and the expression of the interferon alpha/beta receptor component IFNAR1.

Richter MF, Duménil G, Uzé G, Fellous M, Pellegrini S.

J Biol Chem. 1998 Sep 18;273(38):24723-9.

48.

Differences in activity between alpha and beta type I interferons explored by mutational analysis.

Runkel L, Pfeffer L, Lewerenz M, Monneron D, Yang CH, Murti A, Pellegrini S, Goelz S, Uzé G, Mogensen K.

J Biol Chem. 1998 Apr 3;273(14):8003-8.

49.

The amino-terminal region of Tyk2 sustains the level of interferon alpha receptor 1, a component of the interferon alpha/beta receptor.

Gauzzi MC, Barbieri G, Richter MF, Uzé G, Ling L, Fellous M, Pellegrini S.

Proc Natl Acad Sci U S A. 1997 Oct 28;94(22):11839-44.

50.

Structure of the human CRFB4 gene: comparison with its IFNAR neighbor.

Lutfalla G, McInnis MG, Antonarakis SE, Uzé G.

J Mol Evol. 1995 Sep;41(3):338-44.

PMID:
7563119

Supplemental Content

Support Center